Aurobindo Pharma Limited (AUROPHARMA): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Aurobindo Pharma Limited, explained in plain English.
- Aurobindo Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- AUROPHARMA closed at ₹1,795.00 on 18 November 2026.
- Over the past year the shares are up 45.1%, trading between ₹1,106.00 and ₹1,859.90.
- Reported fundamentals show return on equity of 10.71%, a net margin of 10.81%, debt to equity of 21.9.
- Our Pulse grade checklist scores it C (63/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 26.35% with a maximum drawdown of -9.7% and a beta of 0.41 against NIFTY 50.
- Recent coverage: Diwali Muhurat trading stocks+ dividend: Expert picks 2 stocks for Samvat 2083 with record dates next week - Do you own?
- Recent coverage: Cracker stocks this Diwali! Axis Direct selects 10 technical stock with 48% upside potential for Samvat 2083
- Recent coverage: Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Biocon
Figures from the current session. Market open.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Aurobindo Pharma Limited (AUROPHARMA)
₹1,795
▲ 0.9 (+0.05%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 5/51M
+7.68%
3M
+9.12%
6M
+19.63%
1Y
+44.84%
Where it sits in its 52-week range
92%Below 52-week high
3.3%
60.0% above the low
Momentum read
Strong
5/5 checks passed
52-wk high
₹1,855.3
52-wk low
₹1,121.7
Market cap
₹1,03,229 Cr
P/E (trailing)
26.0
Dividend yield
—
ROE
10.71%
Profit margin
10.81%
Revenue growth
23.9%
Price / Book
2.62
Debt / Equity
21.9
EPS (TTM)
69.05
Book value
₹684.73
Beta
0.41
Pulse grade: C, 63 out of 100
Momentum
A- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✓Positive 3-month return
Growth
A- ✓Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
F- ✕Return on equity above Pharma & Healthcare median (14.64%)
- ✕Return on equity above 12%
- ✕Profit margin above Pharma & Healthcare median (13.82%)
Safety
D- ✕Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹10,227 crore · net profit ₹1,126 crore · margin 11.0%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
AUROPHARMA headlines
No AUROPHARMA stories right now.
AUROPHARMA filings & announcements
AUROPHARMA, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
26.35%
Sharpe ratio
1.32
Sortino ratio
2.04
Max drawdown
-9.7%
Daily VaR (95%)
-2.28%
CAGR (1Y)
45.47%
Return skew
0.04
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.